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Abstract
Background: First-degree relatives (FDRs) of people with rheumatoid arthritis (RA) have a fourfold increased risk of
developing RA. The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire was developed to
document symptoms in persons at risk of RA. The aims of this study were (1) to describe symptoms in a cohort of
FDRs of patients with RA overall and stratified by seropositivity and elevated CRP and (2) to determine if patient
characteristics were associated with symptoms suggestive of RA.
Methods: A cross-sectional study of FDRs of patients with RA, in the PREVeNT-RA study, who completed a study
questionnaire, provided a blood sample measured for rheumatoid factor, anti-CCP and CRP and completed the
SPARRA questionnaire. Moderate/severe symptoms and symmetrical, small and large joint pain were identified and
described. Symptoms associated with both seropositivity and elevated CRP were considered suggestive of RA.
Logistic regression was used to determine if symptoms suggestive of RA were associated with patient
characteristics.
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Results: Eight hundred seventy participants provided all data, 43 (5%) were seropositive and 122 (14%) had
elevated CRP. The most frequently reported symptoms were sleep disturbances (20.3%) and joint pain (17.9%).
Symmetrical and small joint pain were 11.3% and 12.8% higher, respectively, in those who were seropositive and
11.5% and 10.7% higher in those with elevated CRP. In the logistic regression model, seropositivity, older age and
feeling depressed were associated with increased odds of small and symmetrical joint pain.
Conclusions: This is the first time the SPARRA questionnaire has been applied in FDRs of patients with RA and has
demonstrated that the presence of symmetrical and small joint pain in this group may be useful in identifying
people at higher risk of developing RA.
Keywords: Rheumatoid arthritis, Pre-RA, Arthralgia, Prevention, Epidemiology, Autoantibodies, Risk factors
Background
It is known that early treatment of RA improves
long-term outcomes and reduces the risk of joint
damage [1]. Studies have shown that patients with RA
may have circulating autoantibodies 5 or more years
prior to developing the disease [2]. Recent studies
have also investigated whether treatment prior to a
clinical diagnosis of RA can actually prevent disease
onset. Results from the PRAIRI (prevention of clinic-
ally manifest RA by B cell directed therapy in the
earliest phase of disease) study has shown that a sin-
gle infusion of rituximab in patients who were sero-
positive (positive for rheumatoid factor (RF) or anti-
citrullinated protein antibodies (ACPA)) but without
clinical synovitis can delay onset of arthritis, though
not prevent it [3]. Further studies are ongoing in pa-
tients deemed at high risk of developing RA, usually
based on the presence of autoantibodies [4]. Identify-
ing people who are at higher risk of developing RA is
not straightforward however, as the aetiology of RA is
incompletely understood and involves the accumula-
tion of both genetic and environmental factors [5].
A preclinical phase, where patients experience symp-
toms prior to the development of overt clinical synovitis,
has been described [6]. The EULAR study group for risk
factors for RA indicated the importance of identifying
symptoms that are associated with subsequent develop-
ment of RA [6]. Few studies have tried to elucidate this
complex of symptoms; however, a qualitative study in
2017 of symptoms in newly diagnosed patients with RA
and patients with arthralgia identified themes of joint
pain, joint swelling and redness, joint stiffness, weakness
and loss of motor control, fatigue, sleeping difficulties
and depressive symptoms and pattern of symptoms and
onset [7]. Often prediction models predicting RA include
symptoms such as swollen and tender joints and morn-
ing stiffness [8, 9].
Given the genetic predisposition to RA, [5] first-degree
relatives (FDRs) of people with RA are a group at higher
risk of developing the disease, with a 2–4 times higher
risk compared to the general population [10]. This group
may therefore offer an opportunity to study the develop-
ment of RA in the pre-clinical phase. A study of FDRs of
patients with RA in North American native (NAN)
population found that FDRs reported more joint symp-
toms than white controls [11]. However, the prevalence
of rheumatic disease in the NAN population is one of
the highest in the world [12] thus may not be represen-
tative of other groups. Therefore, in this study, we aimed
to (1) describe symptoms in a cohort of FDRs of patients
with RA overall, then stratified by seropositivity and ele-
vated CRP, and (2) determine any patient characteristics
associated with symptoms suggestive of RA.
Methods
Study setting
This was a cross-sectional study using data from the
PRe-clinical EValuation of Novel Targets in RA (PRE-
VeNT-RA) study, a cohort study of FDRs of patients
with established RA in the UK. To be included in the co-
hort, individuals needed to be an FDR (parent, sibling or
half-sibling, offspring) of a proband with a diagnosis of
RA (from a rheumatologist) and aged 30 years or over.
Individuals were excluded if they had a previous diagno-
sis of RA or any other inflammatory arthritis.
Study procedures
Individuals who were eligible for inclusion and con-
sented to take part in the PREVeNT-RA study com-
pleted a baseline questionnaire and were provided with a
blood collection kit. The baseline questionnaire collected
information on demographics, medical history, female
reproductive history, lifestyle characteristics, health sta-
tus measured using the EQ-5D-3L health questionnaire
[13] and disability measured using the Health Assess-
ment Questionnaire (HAQ) [14]. The blood collection
kit enabled a blood sample to be taken in primary care,
or at a local rheumatology clinic, and returned to the
study coordinating centre. Individuals who consented to
completing further questionnaires were sent the Symp-
toms in Persons At Risk of Rheumatoid Arthritis
(SPARRA) questionnaire (described below) [15] to
Costello et al. Arthritis Research & Therapy          (2021) 23:210 Page 2 of 11
complete and return to the study coordinating centre.
To be included in this analysis, individuals needed to
have completed a baseline questionnaire, provided a
blood sample and completed the SPARRA
questionnaire.
Blood samples
Blood samples collected prior to SPARRA completion
were used to measure rheumatoid factor (RF) (latex
test), anti-cyclic citrullinated peptide (anti-CCP) (Via-
path CCP – Immunocap) and C-reactive protein (CRP)
(Cormay hsCRP assay). Individuals were considered
seropositive if RF was ≥ 20 U/ml and/or anti-CCP was ≥
7 U/ml. Individuals were considered to have high CRP if
CRP was ≥ 5 mg/L.
Cohort characteristics
The following characteristics were determined from the
baseline questionnaire: age, gender, smoking status
(never smoker, former smoker or current smoker), aver-
age alcohol units per week and body mass index (BMI)
calculated from self-reported height and weight. Individ-
uals were considered to have depression if they indicated
they were moderately or extremely anxious or depressed
in the EQ-5D. Education status was categorised by age
of leaving education (less than 16 years, 16–17 years, 18–
20 years and 21 and over). Socioeconomic status was
measured using index of multiple deprivation (IMD)
quintile [16]. For females, only the following characteris-
tics were determined: ever being pregnant, ever breastfed
a child, ever taken oral contraception and ever taken
hormone replacement therapy (HRT).
SPARRA questionnaire
The SPARRA questionnaire (Additional file 1) collects
self-reported information on the duration, severity
and impact of joint symptoms: pain, swelling, stiff-
ness, burning sensations, tingling sensations and
changes in skin colour; other symptoms: muscle
cramps, weakness, fatigue, emotional distress, concen-
tration difficulties and sleep problems; and severity of
pain in specific locations in the body [15]. For the
purposes of analysis, each symptom was categorised
as being severe if severity was reported as either
moderate or severe. Patterns of joint pain or swelling
indicative of RA were also identified: symmetrical
joint pain was identified if moderate or severe pain
was indicated in any joint on both sides of the body.
Small joint pain was identified if moderate or severe
pain was indicated in the fingers, wrist or toes. Large
joint pain was identified if moderate or severe pain
was indicated in the elbow, shoulder, hip, knee or
ankle.
Analysis
Seropositivity was considered an indicator of ‘higher
risk’ of future RA based on previous literature [2] as
was elevated CRP given it is a broad marker of in-
flammation. Cohort characteristics, overall and strati-
fied by seropositivity and elevated CRP, were
tabulated. A priori, symmetrical and small joint pain
or swelling were considered in keeping with a pos-
sible pre-RA phenotype, and a two-sample test of
proportions was used to identify the proportion, with
95% confidence interval (CI), of individuals with these
features overall and stratified by seropositivity and el-
evated CRP. The same test was used to identify asso-
ciations between any other severe symptoms within
SPARRA and seropositivity or elevated CRP. Where
significant associations were identified, they were con-
sidered suggestive of RA.
Subsequently, characteristics associated with the de-
velopment of RA from previous literature (age, sex,
smoking status, alcohol consumption, BMI, education
level, IMD quintile, depression, elevated CRP and
antibody positivity) [17] were modelled in univariate
and multivariate logistic regression models to deter-
mine if they were associated with each of the
SPARRA items suggestive of RA identified in the first
analysis. As there are some female specific character-
istics known to be associated with RA development
[17], further analyses were conducted in females only
with the following additional characteristics included:
pregnancy, breastfeeding, taking HRT and taking oral
contraceptives. Symptoms not identified as suggestive
of RA were modelled in univariate and multivariate
(i.e. all symptoms together) logistic regression models
to determine if they were associated with the items
suggestive of RA.
Results
As of July 2018, 3114 people had consented to take part
in PREVeNT-RA and 2917 had completed the baseline
questionnaire. Of those, 713 had not provided a blood
sample, 70 had not been sent a SPARRA questionnaire,
317 had not had their blood sample analysed and 947
had not returned the SPARRA questionnaire resulting in
870 people who were eligible for this analysis (Fig. 1).
Those eligible for this study were similar in terms of age
and gender to those who were not eligible, because ei-
ther they did not return the SPARRA questionnaire or
had returned the SPARRA questionnaire but had not
had their blood sample analysed (data not shown).
The mean age of the cohort was 51.8 years (SD 12.1)
and 76.6% (n = 666) were female. A small proportion
were current smokers (6.4%, n = 56), and the majority of
the cohort were Caucasian (97.8%, n = 851). Nearly one
fifth reported depression (19.4%, n = 169), and the most
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frequently reported co-morbidity was hypertension
(15.4%, n = 134). Half of the cohort were in the two least
deprived IMD quintiles (IMD quintile 4: 24.4%, n = 212,
IMD quintile 5: 25.3%, n = 220) (Table 1).
In this cohort, 5% (n = 43) were seropositive, primarily
RF positive (Additional file 2, Table 1) and 14% (n = 122)
had elevated CRP. Those who were seropositive were
older, had a higher proportion with Asian ethnicity and
with diabetes. Those with elevated CRP had a higher
BMI, fewer years of education, were more likely to have
smoked and more likely to have hypertension and dia-
betes (Table 1).
Symptoms
The most frequently reported symptoms were sleep dis-
turbances (20.3%), joint pain (17.9%), fatigue (16.7%) and
distress (16.1%). When stratified by seropositivity, the
proportion reporting muscle cramps was significantly
higher in those who were seropositive (seronegative: n =
84, 10.3% vs seropositive: n = 10, 23.8%) (Table 2 and
Fig. 2A). When stratified by elevated CRP, those with el-
evated CRP had significantly more joint stiffness (normal
CRP: n = 44, 6% vs elevated CRP: n = 25, 20.7%), concen-
tration difficulties (normal CRP: n = 51, 6.9% vs elevated
CRP n = 16, 13.2%) and sleep disturbances (normal CRP:
n = 137, 18.5% vs elevated CRP: n = 38, 31.4%) (Table 2
and Fig. 2B).
Patterns of joint symptoms
The most frequently identified pattern of joint pain
was large joint pain (31%, n = 270). One fifth of the
cohort reported small joint pain (22.8%, n = 198)
and 17.1% (n = 149) reported symmetrical joint pain.
When stratified by seropositivity, a higher propor-
tion of those who were seropositive had small joint
pain (seronegative: n = 183, 22.1% vs seropositive:
n = 15, 34.9%) and symmetrical joint pain (seronega-
tive: n = 137, 16.6% vs seropositive: n = 12, 27.9%)),
though these differences were not statistically sig-
nificant (Table 2 and Fig. 2C). When stratified by
elevated CRP, a significantly higher proportion of
those with elevated CRP had symmetrical (normal
CRP: n = 116, 15.5% vs elevated CRP: n = 33, 27.0%),
small joint (normal CRP: n = 159, 21.3% vs elevated
CRP: n = 39, 32.0%) and large joint pain (normal
CRP: n = 222, 29.7% vs elevated CRP: n = 48, 39.3%)
(Table 2 and Fig. 2D). Only a small number of par-
ticipants reported joint swelling (n = 52); almost all
were seronegative (n = 51) and had normal CRP (n =
44) (Table 2). Therefore, further analysis of joint
Fig. 1 Flowchart of patients included in analysis
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swelling including stratifying by size and symmetry
of joints involved was not possible.
Characteristics associated with small and symmetrical
joint pain
From first principles, having both symmetrical and small
joint pain was considered suggestive of RA and therefore
was incorporated as an alternative outcome measure to
seropositivity. There were 116/870 (13.3%) people who
had both symmetrical and small joint pain. For charac-
teristics, the multivariate logistic regression model indi-
cated that higher age (OR 1.04 (95% CI 1.02, 1.07)),
feeling depressed (OR 2.77 (95% CI 1.65, 4.65)) and be-
ing antibody positive (OR 2.55 (95% CI 1.09, 5.97)) were
associated with increased odds of having both symmet-
rical and small joint pain. Leaving education age 18–20
years, compared to leaving education age 16–17 years,
was associated with reduced odds of symmetrical and
Table 1 Characteristics of cohort overall and stratified by seropositivity and elevated CRP (N = 870)a
Overall Seropositive Elevated CRP
No Yes P value No Yes P value
N 870 827 43 748 122
Sex = female 666 (76.6) 632 (76.4) 34 (79.1) 0.83 564 (75.4) 102 (83.6) 0.062
Age (mean (SDb)) 51.78 (12.1) 51.57 (12.1) 55.67 (10.6) 0.03 51.72 (12.1) 52.12 (11.9) 0.741
BMIb category 0.727 < 0.001
Underweight 14 ( 1.7) 14 ( 1.7) 0 ( 0.0) 13 ( 1.8) 1 ( 0.9)
Normal weight 374 (44.2) 357 (44.4) 17 (40.5) 349 (47.9) 25 (21.4)
Overweight 293 (34.6) 276 (34.3) 17 (40.5) 258 (35.4) 35 (29.9)
Obese 165 (19.5) 157 (19.5) 8 (19.0) 109 (15.0) 56 (47.9)
Age left education 0.836 0.035
Less than 16 years 51 ( 6.0) 49 ( 6.0) 2 ( 4.8) 43 ( 5.8) 8 ( 6.7)
16–17 years 333 (38.9) 319 (39.1) 14 (33.3) 278 (37.7) 55 (46.2)
18–20 years 209 (24.4) 198 (24.3) 11 (26.2) 176 (23.8) 33 (27.7)
21+ years 264 (30.8) 249 (30.6) 15 (35.7) 241 (32.7) 23 (19.3)
Smoking status 0.729 0.08
Never smoker 498 (57.3) 471 (57.0) 27 (62.8) 439 (58.8) 59 (48.4)
Former smoker 315 (36.2) 301 (36.4) 14 (32.6) 260 (34.8) 55 (45.1)
Current smoker 56 ( 6.4) 54 ( 6.5) 2 ( 4.7) 48 ( 6.4) 8 ( 6.6)
Ethnicity 0.001 0.094
White 851 (97.9) 811 (98.2) 40 (93.0) 734 (98.3) 117 (95.9)
Mixed 4 ( 0.5) 4 ( 0.5) 0 ( 0.0) 4 ( 0.5) 0 ( 0.0)
Asian 8 ( 0.9) 5 ( 0.6) 3 ( 7.0) 6 ( 0.8) 2 ( 1.6)
Black 4 ( 0.5) 4 ( 0.5) 0 ( 0.0) 2 ( 0.3) 2 ( 1.6)
Chinese 2 ( 0.2) 2 ( 0.2) 0 ( 0.0) 1 ( 0.1) 1 ( 0.8)
Average units of alcohol per week (mean (SDb)) 7.44 (8.83) 7.40 (8.76) 8.21 (10.20) 0.559 7.53 (8.94) 6.90 (8.14) 0.472
Diabetes mellitus 28 ( 3.2) 23 ( 2.8) 5 (11.9) 0.005 20 ( 2.7) 8 ( 6.6) 0.048
Psoriasis 38 ( 4.4) 37 ( 4.5) 1 ( 2.4) 0.789 30 ( 4.0) 8 ( 6.6) 0.298
Hypertension 134 (15.5) 126 (15.3) 8 (18.6) 0.714 104 (14.0) 30 (24.8) 0.003
Depression 169 (19.7) 164 (20.1) 5 (11.6) 0.245 138 (18.6) 31 (26.3) 0.068
IMDb quintile 0.587 0.749
1 (most deprived) 64 ( 7.9) 61 ( 7.9) 3 ( 7.5) 56 ( 8.0) 8 ( 6.8)
2 133 (16.3) 126 (16.3) 7 (17.5) 109 (15.6) 24 (20.5)
3 186 (22.8) 181 (23.4) 5 (12.5) 160 (22.9) 26 (22.2)
4 212 (26.0) 199 (25.7) 13 (32.5) 182 (26.1) 30 (25.6)
5 (least deprived) 220 (27.0) 208 (26.8) 12 (30.0) 191 (27.4) 29 (24.8)
aData are shown as number (percentage) unless otherwise indicated. bSD, standard deviation; BMI, body mass index; IMD, Index of Multiple Deprivation
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small joint pain (OR 0.51 (95% CI 0.27, 0.97) (Table 3).
In the model with females only, higher age (OR 1.03
(95% CI 1.01, 1.06)) and depression (OR 2.92 (95% CI
1.58, 5.39)) remained associated with increased odds of
symmetrical and small joint pain. In addition, ever using
HRT was associated with increased odds of symmetrical
and small joint pain (OR 2.21 (95% CI 1.15, 4.23)) (Add-
itional file 2, Table 2).
Symptoms associated with small and symmetrical joint
pain
Those with small and symmetrical joint pain reported
more symptoms overall. The multivariate logistic regres-
sion model indicated that joint pain, joint stiffness, joint
burning, joint tingling and fatigue were all associated
with increased odds of symmetrical and small joint pain
(Table 4). Similar results were seen in the female only
model (Additional file 2, Table 3).
Discussion
This is the first time that symptoms have been captured
in a cohort of FDRs of patients with RA, using a ques-
tionnaire that that captures data related to the full
spectrum of symptoms associated with the early stages
of RA. We found that symmetrical and small joint pain
was associated with antibody positivity and higher levels
of inflammation in the blood. The study also identified
associations between increasing age, depression and
seropositivity and odds of having both symmetrical and
small joint pain; whereas education after age 16 was as-
sociated with reduced odds of having both symmetrical
and small joint pain. Other reported symptoms did not
Table 2 Symptoms and pattern of joint pain, overall and stratified by seropositivity and elevated CRP












147 (18.0) 7 (16.3) − 1.76 (− 13.1 to 9.59) 128 (17.4) 26 (21.5) 4.12 (− 3.69 to 11.93)
Joint swelling 53 (
6.2)
52 ( 6.4) 1 ( 2.4) 44 ( 6.0) 9 ( 7.4) 1.48 (− 3.5 to 6.45)
Joint stiffness 100
(11.7)
94 (11.5) 6 (14.3) 2.77 (− 8.04 to 13.57) 75 (10.2) 25 (20.7) 10.48 (2.95 to 18.02)
Joint burning 32 (
3.7)
31 ( 3.8) 1 ( 2.4) 24 ( 3.3) 8 ( 6.6) 3.35 (− 1.26 to 7.96)
Joint tingling 27 (
3.2)
27 ( 3.3) 0 ( 0.0) 22 ( 3.0) 5 ( 4.2) 1.18 (− 2.6 to 4.96)
Colour change 15 (
1.8)
15 ( 1.8) 0 ( 0.0) 11 ( 1.5) 4 ( 3.3) 1.81 (− 1.49 to 5.12)
Cramp 94
(10.9)
84 (10.3) 10 (23.8) 13.53 (0.48 to 26.58) 80 (10.8) 14 (11.7) 0.84 (− 5.32 to 7.01)
Weakness 77 (
9.0)
71 ( 8.7) 6 (14.3) 5.57 (− 5.18 to 16.33) 62 ( 8.4) 15 (12.4) 3.97 (− 2.23 to 10.18)
Fatigue 143
(16.7)
134 (16.4) 9 (21.4) 4.99 (− 7.68 to 17.65) 117 (15.9) 26 (21.5) 5.59 (− 2.19 to 13.37)
Distress 138
(16.1)










163 (19.9) 12 (28.6) 8.64 (− 5.29 to 22.58) 137 (18.5) 38 (31.4) 12.87 (4.13 to 21.6)





137 (16.6) 12 (27.9) 11.34 (− 2.3 to 24.99) 116 (15.5) 33 (27.0) 11.54 (3.24 to 19.84)
Small joint pain 198
(22.8)
183 (22.1) 15 (34.9) 12.76 (− 1.77 to 27.28) 159 (21.3) 39 (32.0) 10.71 (1.93 to 19.49)
Large joint pain 270
(31.0)
256 (31.0) 14 (32.6) 1.6 (− 12.75 to 15.96) 222 (29.7) 48 (39.3) 9.67 (0.4 to 18.93)
aDifference in proportions is considered significantly different from zero if the 95% CI does not include zero
bDifference in proportions not able to be calculated if the number in one strata is less than 5 as the CI cannot be (reliably) calculated
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show a clear pattern helpful for identifying patients at
risk of RA in a cross-sectional setting; this may be due
to the broad nature of the symptoms. Symmetrical and
small joint pain have also been associated with RA in
previous studies [17], highlighting that the sections of
the SPARRA questionnaire where symmetrical and small
joint pain can be identified may be useful for identifying
people at high risk of developing RA.
It was of interest that depression was strongly asso-
ciated with symmetrical and small joint pain. Depres-
sion has been found to be highly prevalent in patients
with RA [18]. Depression and RA have also been
shown to have a bidirectional association, with the
presence of pre-existing depression increasing the
likelihood of developing RA, and the presence of RA
increasing the likelihood of developing depression
[19]. Further, in a study of patients with seropositive
arthralgia, depressive mood was found to be associ-
ated with musculoskeletal symptoms but not arthritis
development [20], though recent studies have found
depression to be associated with subsequent RA [21,
22]. In our study, depression was highly associated
with having small and symmetrical joint pain and also
large joint pain (results not shown). However, depres-
sion in our study was measured relatively crudely
with a single question in the EQ-5D questionnaire,
and therefore, this relationship warrants further inves-
tigation in other pre-RA cohorts. Our finding that
low educational attainment was associated with sym-
metrical and small joint pain is also in keeping with
previous inflammatory arthritis literature; in the EPIC
to NOAR study, Lahiri et al. identified that rates of
inflammatory polyarthritis were lower in those with
degree level education [16].
Fig. 2 Interval plots of symptoms and patterns of joint symptoms stratified by seropositivity and elevated CRP
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A surprising finding was that the proportion of current
and former smokers was lower in those who were sero-
positive compared to those who were seronegative. This
is most likely to be due to the small number of people
who were seropositive (only 5% of this cohort), though
the proportion who were seropositive was similar in a
Dutch FDR cohort with similar patient characteristics,
where 6.6% were seropositive [23]. The subset of the
PREVeNT-RA cohort used for this study had few co-
morbidities and may have had healthier lifestyles than
the broader UK population. For example, the proportion
of the cohort who were current smokers was low, and
only 6.4% were current smokers, which is lower than
current UK wide estimates of 15% [24]. Similarly, only
3.2% of participants self-reported diabetes, whereas the
2016 estimated prevalence in England was 8.6% [25].
Overall 52.7% had a BMI that was overweight or obese
which is lower than 64% estimated to be overweight or
obese in the UK in 2017 [26]. However, a high propor-
tion (19.4%) indicated feeling moderately or severely
anxious or depressed, slightly greater than the overall
UK estimates of 15.7% [27]. This means the study popu-
lation may not be fully representative of the general FDR
population, perhaps due to non-responder bias, as to be
included in this study participants needed to have com-
pleted and returned the SPARRA questionnaire.
Table 3 Characteristics and associations with symmetrical and small joint pain (N = 764)a
Characteristic Number (%) without
symmetrical and small joint
pain, unless otherwise
specified










Age (continuous, mean (SDc)) 50.9 (11.9) 57.4 (12.0) 1.05 (1.03, 1.06) 1.04 (1.02, 1.07)
Sex Male 156 (87.2) 23 (12.9) Reference Reference
Female 514 (87.9) 71 (12.1) 0.94 (0.57, 1.55) 1.18 (0.67, 2.06)
Smoking status Never smoker 401 (89.7) 46 (10.3) Reference Reference
Former
smoker
235 (85.5) 40 (14.6) 1.48 (0.94, 2.33) 1.28 (0.78, 2.11)
Current
smoker
34 (81.0) 8 (19.1) 2.05 (0.90, 4.70) 1.55 (0.61, 3.92)
Average units of alcohol consumed per
week (continuous) (mean (SDc))
7.5 (8.8) 7.0 (8.9) 1.00 (0.97, 1.02) 0.99 (0.97, 1.02)
BMIc category Underweight 13 (100) 0 Null Null
Normal
weight
309 (91.7) 28 (8.3) Reference Reference
Overweight 220 (84.0) 42 (16.0) 2.11 (1.27, 3.50) 1.57 (0.91, 2.71)





35 (74.5) 12 (25.5) 1.79 (0.87, 3.71) 0.84 (0.37, 1.91)
16–17 years 246 (84.0) 47 (16.0) Reference Reference
18–20 years 176 (92.2) 15 (7.9) 0.45 (0.24, 0.82) 0.51 (0.27, 0.97)
21+ years 213 (91.4) 20 (8.6) 0.49 (0.28, 0.86) 0.63 (0.35, 1.14)
IMDc quintile 1 48 (80.0) 12 (20.0) Reference Reference
2 109 (89.3) 13 (10.7) 0.48 (0.20, 1.12) 0.51 (0.2, 1.31)
3 158 (89.8) 18 (10.2) 0.46 (0.21, 1.01) 0.47 (0.2, 1.13)
4 171 (86.4) 27 (13.6) 0.63 (0.30, 1.34) 0.65 (0.28, 1.53)
5 184 (88.5) 24 (11.5) 0.52 (0.24, 1.12) 0.51 (0.21, 1.22)
Depression No 564 (90.4) 60 (9.6) Reference Reference
Yes 106 (75.7) 34 (24.3) 3.02 (1.89, 4.82) 2.77 (1.65, 4.65)
CRPc Normal 587 (88.7) 75 (11.3) Reference Reference
Elevated 83 (81.4) 19 (20.2) 1.79 (1.03, 3.12) 1.19 (0.63, 2.25)
Antibody status Seronegative 642 (88.3) 85 (11.7) Reference Reference
Seropositive 28 (75.7) 9 (24.3) 2.43 (1.11, 5.32) 2.55 (1.09, 5.97)
aIncluded only complete cases. b Odds ratio is considered significantly different from one if the 95% CI does not include one. cSD, standard deviation; BMI, body
mass index; IMD, Index of Multiple Deprivation, CRP: C-reactive protein
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Only a few studies to date have sought to describe
symptoms in unaffected FDRs of patients with RA,
mainly reporting joint symptoms. Our findings were
similar those of a study of unaffected FDRs in the USA
(the SERA cohort) where 23% reported inflammatory
joint signs, defined as tender or swollen RA-specific
joints (hands, wrists, feet and elbow) [28] which is simi-
lar to the proportion reporting small joint pain in this
study (22.8%). However, in a different study of NAN
FDRs, joint symptoms were more frequently reported
compared to this study, with 55% reporting pain in the
hands compared to 18% reporting pain in any joint in
this study [11]; this may be due to differences between
the populations used as NANs have higher prevalence of
RA [12]. Musculoskeletal symptoms have also been de-
scribed in a non-FDR population, where symptoms in
consulters to UK primary care with a musculoskeletal
(MSK) condition were compared to symptoms in a
matched population who consulted for a non-MSK con-
dition. It was found 42% MSK consulters reported sym-
metrical joint pain, so too did 37% of the matched
sample [29]. For both groups, this was higher than in
our study where 17% reported symmetrical joint pain.
However, the patients in that study were older than in
our study and likely to be more unwell as they were con-
sulting at primary care. Studies of patients who were
seropositive, but not specifically FDRs, found similar re-
sults to our study. Rakieh et al found that found tender-
ness in small joints to be associated with progression to
inflammatory arthritis in patients who were anti-CCP
positive [9]. Another small study included 10 people
who were ACPA-positive or IgM RF-positive and had
symmetrical small joint arthralgia; of those, 6 went onto
to develop arthritis [30]. This suggests symmetrical and
small joint pain may be important to identify in at-risk
populations and that questionnaires such as this will
have utility on screening such groups.
This was a large prospective study of unaffected
FDRs of patients with RA in the PREVeNT-RA co-
hort, and the use of the SPARRA questionnaire
allowed the collection of detailed symptom data.
However, there were some limitations. It was a cross-
sectional study; thus, we cannot infer any time
dependent or causal relationships. Although the
PREVeNT-RA study has been running for 7 years,
there are currently too few cases of RA to analyse
and validate the SPARRA questionnaire against the
outcome of a clinical RA diagnosis. We therefore
used seropositivity as proxy measures of this outcome,
indicating those at ‘higher risk’ of future RA. We ac-
knowledge, however, that not all patients with RA are
seropositive nor all seropositive individuals develop
RA [5], particularly those who are only RF positive
[30]. Our study was also not able to recall these pa-
tients for more detailed clinical assessment, such as
joint examination; therefore, there may have been un-
diagnosed RA or other inflammatory conditions. This
could mean some characteristics identified as putting
a person at high risk of RA, could be symptoms of
RA that has already developed, or conversely could be
due to another condition. Enhancing this question-
naire with additional clinical and imaging assessments
may identify RA at a very early stage for interven-
tions, and such future studies are planned. Finally,
our response rate to the questionnaire was low, albeit
within the range expected for surveys [31]. The
SPARRA questionnaire is long, and some subjects fed
back some difficulties in understanding all the
Table 4 Symptoms and associations with symmetrical and small joint pain (N = 829)
Symptom present Number without
symmetrical and
small joint pain (%)
Number with small and





odds ratio (95% confidence interval)b
Joint pain 51 (7.5) 53 (36.8) 7.2 (4.7, 11.3) 2.16 (1.15, 4.09)
Joint swell 84 (10.8) 20 (41.7) 5.9 (3.2, 11.0) 1.03 (0.40, 2.64)
Joint stiff 59 (8.0) 45 (48.4) 10.8 (6.6, 17.5) 3.00 (1.50, 6.00)
Joint burn 88 (11.0) 16 (57.1) 10.8 (4.9, 23.6) 2.91 (1.03, 8.24)
Joint tingling 85 (10.6) 19 (73.1) 22.9 (9.4, 56.1) 7.32 (2.49, 21.49)
Colour 100 (12.3) 4 (28.6) 2.9 (0.9, 9.3) 0.52 (0.10, 2.84)
Cramp 78 (10.6) 26 (28.9) 3.4 (2.1, 5.7) 1.47 (0.75, 2.88)
Weakness 73 (9.7) 31 (42.5) 6.9 (4.1, 11.7) 1.28 (0.61, 2.70)
Fatigue 56 (8.1) 48 (34.5) 6.0 (3.8, 9.3) 2.03 (1.06, 3.89)
Distress 69 (9.9) 35 (6.5) 3.3 (2.1, 5.2) 0.89 (0.44, 1.79)
Concentration difficulties 80 (10.4) 24 (39.3) 5.6 (3.2, 9.8) 0.88 (0.36, 2.15)
Sleep disturbances 58 (8.8) 46 (27.2) 3.9 (2.5, 6.0) 1.31 (0.71, 2.42)
aAll symptoms modelled together, with no other adjustment. b Odds ratio is considered significantly different from one if the 95% CI does not include one
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questions. Our work however may point the way to
how the questionnaire could be refined and perhaps
shortened without any loss of its discriminatory
power.
Conclusions
This study of FDRs of patients with RA found that sym-
metrical and small joint pain was associated with anti-
body positivity and higher levels of inflammation in the
blood, which may be an indicator of people who may be
at higher risk of developing RA.
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